Tags

Type your tag names separated by a space and hit enter

Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72).
Diabetologia 2005; 48(5):868-77D

Abstract

AIMS/HYPOTHESIS

This study estimated the economic efficiency (1) of intensive blood glucose control and tight blood pressure control in patients with type 2 diabetes who also had hypertension, and (2) of metformin therapy in type 2 diabetic patients who were overweight.

METHODS

We conducted cost-utility analysis based on patient-level data from a randomised clinical controlled trial involving 4,209 patients with newly diagnosed type 2 diabetes conducted in 23 hospital-based clinics in England, Scotland and Northern Ireland as part of the UK Prospective Diabetes Study (UKPDS). Three different policies were evaluated: intensive blood glucose control with sulphonylurea/insulin; intensive blood glucose control with metformin for overweight patients; and tight blood pressure control of hypertensive patients. Incremental cost : effectiveness ratios were calculated based on the net cost of healthcare resources associated with these policies and on effectiveness in terms of quality-adjusted life years gained, estimated over a lifetime from within-trial effects using the UKPDS Outcomes Model.

RESULTS

The incremental cost per quality-adjusted life years gained (in year 2004 UK prices) for intensive blood glucose control was 6,028 UK pounds, and for blood pressure control was 369 UK pounds. Metformin therapy was cost-saving and increased quality-adjusted life expectancy.

CONCLUSIONS/INTERPRETATION

Each of the three policies evaluated has a lower cost per quality-adjusted life year gained than that of many other accepted uses of healthcare resources. The results provide an economic rationale for ensuring that care of patients with type 2 diabetes corresponds at least to the levels of these interventions.

Authors+Show Affiliations

Health Economics Research Centre, Department of Public Health, University of Oxford, Old Road Campus, Headington, Oxford OX3 7LF, UK. philip.clarke@dphpc.ox.ac.ukNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

15834550

Citation

Clarke, P M., et al. "Cost-utility Analyses of Intensive Blood Glucose and Tight Blood Pressure Control in Type 2 Diabetes (UKPDS 72)." Diabetologia, vol. 48, no. 5, 2005, pp. 868-77.
Clarke PM, Gray AM, Briggs A, et al. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia. 2005;48(5):868-77.
Clarke, P. M., Gray, A. M., Briggs, A., Stevens, R. J., Matthews, D. R., & Holman, R. R. (2005). Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia, 48(5), pp. 868-77.
Clarke PM, et al. Cost-utility Analyses of Intensive Blood Glucose and Tight Blood Pressure Control in Type 2 Diabetes (UKPDS 72). Diabetologia. 2005;48(5):868-77. PubMed PMID: 15834550.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). AU - Clarke,P M, AU - Gray,A M, AU - Briggs,A, AU - Stevens,R J, AU - Matthews,D R, AU - Holman,R R, AU - ,, Y1 - 2005/04/15/ PY - 2004/08/28/received PY - 2004/12/03/accepted PY - 2005/4/19/pubmed PY - 2005/9/21/medline PY - 2005/4/19/entrez SP - 868 EP - 77 JF - Diabetologia JO - Diabetologia VL - 48 IS - 5 N2 - AIMS/HYPOTHESIS: This study estimated the economic efficiency (1) of intensive blood glucose control and tight blood pressure control in patients with type 2 diabetes who also had hypertension, and (2) of metformin therapy in type 2 diabetic patients who were overweight. METHODS: We conducted cost-utility analysis based on patient-level data from a randomised clinical controlled trial involving 4,209 patients with newly diagnosed type 2 diabetes conducted in 23 hospital-based clinics in England, Scotland and Northern Ireland as part of the UK Prospective Diabetes Study (UKPDS). Three different policies were evaluated: intensive blood glucose control with sulphonylurea/insulin; intensive blood glucose control with metformin for overweight patients; and tight blood pressure control of hypertensive patients. Incremental cost : effectiveness ratios were calculated based on the net cost of healthcare resources associated with these policies and on effectiveness in terms of quality-adjusted life years gained, estimated over a lifetime from within-trial effects using the UKPDS Outcomes Model. RESULTS: The incremental cost per quality-adjusted life years gained (in year 2004 UK prices) for intensive blood glucose control was 6,028 UK pounds, and for blood pressure control was 369 UK pounds. Metformin therapy was cost-saving and increased quality-adjusted life expectancy. CONCLUSIONS/INTERPRETATION: Each of the three policies evaluated has a lower cost per quality-adjusted life year gained than that of many other accepted uses of healthcare resources. The results provide an economic rationale for ensuring that care of patients with type 2 diabetes corresponds at least to the levels of these interventions. SN - 0012-186X UR - https://www.unboundmedicine.com/medline/citation/15834550/Cost_utility_analyses_of_intensive_blood_glucose_and_tight_blood_pressure_control_in_type_2_diabetes__UKPDS_72__ L2 - https://dx.doi.org/10.1007/s00125-005-1717-3 DB - PRIME DP - Unbound Medicine ER -